The prognosis of agenesis of the corpus callosum might mostly be favourable

G. P. Rameli, N. Zanda, M. Wyttenbach, L. Bronz, A. Schneider

a Department of Paediatrics, Ospedale San Giovanni, Bellinzona, Switzerland
b Department of Radiology, Ospedale San Giovanni, Bellinzona, Switzerland
c Department of Obstetrics and Gynaecology, Ospedale San Giovanni, Bellinzona, Switzerland
d Division of Rehabilitation, Department of Clinical Neurosciences and Dermatology, University of Geneva, Switzerland

Summary

The post-natal development of 6 patients with complete agenesis of the corpus callosum was assessed. The diagnosis of agenesis of the corpus callosum had been suspected prenatally in 3 cases. In the remaining 3 cases diagnostic neuro-imaging was performed because of partial seizures (n = 2) and pendular nystagmus (n = 1). The neurological examination was normal in all patients with the exception of nystagmus in one. The neuro-developmental outcome was found to be normal in all 6 patients. In conclusion, these data suggest that good outcome is predominant in agenesis of the corpus callosum.

Key words: Agenesis of corpus callosum; magnetic resonance imaging; epileptic seizures

Introduction

Normally, the corpus callosum begins to develop at about 12 weeks of gestation and can be sonographically appreciated by 18 to 20 weeks of gestation [1]. Since agenesis of the corpus callosum (ACC) usually occurs in combination with other malformations, children with ACC mostly present with intellectual retardation, seizures, hydrocephalus, and cerebral palsy. Isolated ACC mostly results in pleiotropic, rather mild clinical manifestations that are mostly recognised at school age but is rarely entirely asymptomatic [2, 3].

We present a consecutive series of individuals with complete ACC and a rather long follow up encountered in a single paediatric neurology practice to further the clinical profile of this malformation.

Case report

Our experience includes 6 patients (2 female and 4 male subjects) currently aged 2 to 27 years with complete ACC (table 1). In theses patients the family history was negative with respect to ACC. The patients were born at term after an uneventful pregnancy with the exception of patient 1, who was delivered by caesarian section at 34 weeks. Neonatal weight, height and head circumference were appropriate for gestational age and the clinical examination normal in the 6 patients.

The diagnosis of ACC had been suspected prenatally in 3 cases (patient 1, 2 and 3) by means of a routine mid-gestation sonography revealing a bilateral ventricular enlargement [4, 5]. In these patients soon after birth magnetic resonance imaging disclosed the characteristic abnormalities of complete ACC [6].

Findings consistent with pendular nystagmus were noted in patient 4 at the age of 4 weeks. Fundoscopy and electroretinography were normal. At the age of 8 months magnetic resonance imaging disclosed complete ACC. Patients 5 and 6 presented with a history of partial complex seizures at the age of 3 and 11 years respectively. Electroencephalography disclosed some interhemispheric asynchronism and a focus of delta-theta waves in the temporoparietal region on the right (patient 5) and the left side (patient 6), but no epileptic discharges. In patient 5 medical treatment with carbamazepine was instituted and withdrawn after two years without seizures. In patient 6 control of seizures was achieved combining carbamazepine with valproic acid. In both patients magnetic resonance imaging disclosed complete ACC without any associated abnormalities.

The development of the 6 patients was very recently assessed (table 1). The neurological examination including cranial nerve examination, motor and sensory examinations and evaluation of coordination was normal in all patients with the exception of nystagmus in patient 4. The
Wechsler Intelligence Scale for Children-Revised (patient 1), the Griffiths Scales of Mental Development (patients 2 and 3), the Kaufmann Assessment Battery for Children (patients 4 and 6), or the Raven Standard Progressive Matrices (patient 5) were used to assess the neuro-developmental outcome, which was found to be normal in all cases.

**Discussion**

The estimated prevalence of ACC is 0.3–0.5% in the general population and 2.3% in developmentally disabled individuals [7]. It is usually assumed that, although a normal asymptomatic outcome of ACC can occur, it is the exception rather than the rule [2, 3]. The present data suggest that good outcome is predominant in isolated ACC, as indicated by the fact that no dysfunction was disclosed in 3 patients and a mild dysfunction, including partial, rather benign epilepsy or nystagmus, in the remaining 3 patients.

The discrepancy between the traditional assumption of poor outcome and our experience relates to the fact that in the past ACC was demonstrated by neuroimaging in infants with a clinically relevant nervous system dysfunction. Routine midgestation sonography has changed things [4, 5]: nowadays isolated ACC is rather commonly demonstrated during foetal life. Studies dealing with prenatally detected ACC report that isolated ACC has an excellent prognosis with an up to 85% chance of a normal outcome [8, 9]. However, duration of follow-up in these studies is often short, suggesting that late onset neurological signs may be missed. It has been suggested that the corpus callosum is important for tactuo-motor learning and bimanual coordination [10, 11]. It is therefore tempting to assume that some subtle but practically irrelevant abnormalities in tactuo-motor learning and bimanual coordination is likely to be present in our patients with ACC, who were mainly studied using global scales.

The outcome is obviously less favourable in children with ACC in the context of a recognised, extensive cerebral dysgenesis syndrome [2, 3].

In conclusion our obviously preliminary data demonstrate that isolated ACC could have a favourable outcome. However, a long follow-up is advised to diagnose minor abnormalities.

**Correspondence:**
Dr. G.P. Ramelli  
Department of Paediatrics  
Ospedale San Giovanni  
CH-6500 Bellinzona  
Switzerland  
E-Mail: gpramelli@bluewin.ch

**Table 1**

<table>
<thead>
<tr>
<th>Number</th>
<th>Gender</th>
<th>Age at diagnosis</th>
<th>Presenting clinical features</th>
<th>Current age (years)</th>
<th>Neuro-developmental assessment test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Female</td>
<td>28th gestational week</td>
<td>None</td>
<td>10</td>
<td>Wechslera</td>
<td>102</td>
</tr>
<tr>
<td>2</td>
<td>Male</td>
<td>26th gestational week</td>
<td>None</td>
<td>2</td>
<td>Griffithb</td>
<td>Normal</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>24th gestational week</td>
<td>None</td>
<td>2</td>
<td>Griffithb</td>
<td>Normal</td>
</tr>
<tr>
<td>4</td>
<td>Male</td>
<td>8 months</td>
<td>Pendular nystagmus</td>
<td>11</td>
<td>Kaufmannc</td>
<td>116</td>
</tr>
<tr>
<td>5</td>
<td>Male</td>
<td>13 years</td>
<td>Partial seizures (3 years of age)</td>
<td>25</td>
<td>Ravenb</td>
<td>110</td>
</tr>
<tr>
<td>6</td>
<td>Female</td>
<td>3 years</td>
<td>Partial seizures (11 years of age)</td>
<td>9</td>
<td>Kaufmannc</td>
<td>97</td>
</tr>
</tbody>
</table>

a Wechsler Intelligence Scale for Children-Revised; b Griffith Scales of Mental Development; c Kaufmann Assessment Battery for Children; d Raven Standard Progressive Matrices.

**References**

The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

• SMW’s impact factor has been steadily rising, to the current 1.537
• Open access to the publication via the Internet, therefore wide audience and impact
• Rapid listing in Medline
• LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
• No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
• Peer review based on a broad spectrum of international academic referees
• Assistance of our professional statistician for every article with statistical analyses
• Fast peer review, by e-mail exchange with the referees
• Prompt decisions based on weekly conferences of the Editorial Board
• Prompt notification on the status of your manuscript by e-mail
• Professional English copy editing
• No page charges and attractive colour offprints at no extra cost

Editorial Board
Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich
( Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne

International Advisory Committee
Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haeffeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

Impact factor Swiss Medical Weekly

All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch